Jaun­dice drug for in­fants re­ject­ed by FDA, shak­ing up Mallinck­rodt's plans for new­ly-ac­quired stannso­porfin

It’s of­fi­cial. Mallinck­rodt’s new­ly-ac­quired jaun­dice drug just got kicked back by the FDA.

The Eng­land-based drug­mak­er was ex­pect­ing omi­nous news af­ter the agency’s ad­vi­so­ry com­mit­tee …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER